These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 33075795)

  • 1. Efficacy of a Novel Second-Generation Somatostatin-Dopamine Chimera (TBR-065) in Human Medullary Thyroid Cancer: A Preclinical Study.
    Dicitore A; Cantone MC; Gaudenzi G; Saronni D; Carra S; Borghi MO; Albertelli M; Ferone D; Hofland LJ; Persani L; Vitale G
    Neuroendocrinology; 2021; 111(10):937-950. PubMed ID: 33075795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vandetanib versus Cabozantinib in Medullary Thyroid Carcinoma: A Focus on Anti-Angiogenic Effects in Zebrafish Model.
    Carra S; Gaudenzi G; Dicitore A; Saronni D; Cantone MC; Plebani A; Ghilardi A; Borghi MO; Hofland LJ; Persani L; Vitale G
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33809722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-2 and lanreotide in the treatment of medullary thyroid cancer: in vitro and in vivo studies.
    Vitale G; Lupoli G; Guarrasi R; Colao A; Dicitore A; Gaudenzi G; Misso G; Castellano M; Addeo R; Facchini G; Del Prete S; Caraglia M
    J Clin Endocrinol Metab; 2013 Oct; 98(10):E1567-74. PubMed ID: 23884781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cAMP analogs have potent anti-proliferative effects on medullary thyroid cancer cell lines.
    Dicitore A; Grassi ES; Caraglia M; Borghi MO; Gaudenzi G; Hofland LJ; Persani L; Vitale G
    Endocrine; 2016 Jan; 51(1):101-12. PubMed ID: 25863490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Octreotide and pasireotide effects on medullary thyroid carcinoma (MTC) cells growth, migration and invasion.
    Giardino E; Catalano R; Mangili F; Barbieri AM; Treppiedi D; Elli FM; Dolci A; Contarino A; Spada A; Arosio M; Mantovani G; Peverelli E
    Mol Cell Endocrinol; 2021 Jan; 520():111092. PubMed ID: 33248230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metformin inhibits growth and decreases resistance to anoikis in medullary thyroid cancer cells.
    Klubo-Gwiezdzinska J; Jensen K; Costello J; Patel A; Hoperia V; Bauer A; Burman KD; Wartofsky L; Vasko V
    Endocr Relat Cancer; 2012 Jun; 19(3):447-56. PubMed ID: 22389381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term effects of somatostatin analogues in rat GH-secreting pituitary tumor cell lines.
    Dicitore A; Saronni D; Gaudenzi G; Carra S; Cantone MC; Borghi MO; Persani L; Vitale G
    J Endocrinol Invest; 2022 Jan; 45(1):29-41. PubMed ID: 34128215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Somatostatin, but not somatostatin receptor subtypes 2 and 5 selective agonists, inhibits calcitonin secretion and gene expression in the human medullary thyroid carcinoma cell line, TT.
    Zatelli MC; Tagliati F; Taylor JE; Piccin D; Culler MD; degli Uberti EC
    Horm Metab Res; 2002 May; 34(5):229-33. PubMed ID: 12063634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antineoplastic Activity of an Old Natural Antidiabetic Biguanide on the Human Thyroid Carcinoma Cell Line.
    Nozhat Z; Zarkesh M; Baldini E; Mohammadi-Yeganeh S; Azizi F; Hedayati M
    Anticancer Agents Med Chem; 2022; 22(4):713-720. PubMed ID: 33461474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TBR-760, a Dopamine-Somatostatin Compound, Arrests Growth of Aggressive Nonfunctioning Pituitary Adenomas in Mice.
    Halem HA; Hochgeschwender U; Rih JK; Nelson R; Johnson GA; Thiagalingam A; Culler MD
    Endocrinology; 2020 Aug; 161(8):. PubMed ID: 32591776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of the ability of a, second-generation SST-DA chimeric molecule, TBR-065, to suppress GH secretion from human GH-secreting adenoma cells.
    Cuny T; Graillon T; Defilles C; Datta R; Zhang S; Figarella-Branger D; Dufour H; Mougel G; Brue T; Landsman T; Halem HA; Culler MD; Barlier A; Saveanu A
    Pituitary; 2021 Jun; 24(3):351-358. PubMed ID: 33433890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic antitumour activity of RAF265 and ZSTK474 on human TT medullary thyroid cancer cells.
    Bertazza L; Barollo S; Radu CM; Cavedon E; Simioni P; Faggian D; Plebani M; Pelizzo MR; Rubin B; Boscaro M; Pezzani R; Mian C
    J Cell Mol Med; 2015 Sep; 19(9):2244-52. PubMed ID: 26081844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrent Metastatic Medullary Thyroid Carcinoma: A Case of Sustained Response to Prolonged Treatment with Somatostatin Analogues.
    Cano JM; Galán R; López R
    Thyroid; 2017 Nov; 27(11):1450-1455. PubMed ID: 28927353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective activation of somatostatin receptor subtypes differentially modulates secretion and viability in human medullary thyroid carcinoma primary cultures: potential clinical perspectives.
    Zatelli MC; Piccin D; Tagliati F; Bottoni A; Luchin A; Vignali C; Margutti A; Bondanelli M; Pansini GC; Pelizzo MR; Culler MD; Degli Uberti EC
    J Clin Endocrinol Metab; 2006 Jun; 91(6):2218-24. PubMed ID: 16569735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant leukemia inhibitory factor suppresses human medullary thyroid carcinoma cell line xenografts in mice.
    Starenki D; Singh NK; Jensen DR; Peterson FC; Park JI
    Cancer Lett; 2013 Oct; 339(1):144-51. PubMed ID: 23856028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical Evaluation of Novel Tyrosine-Kinase Inhibitors in Medullary Thyroid Cancer.
    Saronni D; Gaudenzi G; Dicitore A; Carra S; Cantone MC; Borghi MO; Barbieri A; Mignani L; Hofland LJ; Persani L; Vitale G
    Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical testing of selective Aurora kinase inhibitors on a medullary thyroid carcinoma-derived cell line.
    Tuccilli C; Baldini E; Prinzi N; Morrone S; Sorrenti S; Filippini A; Catania A; Alessandrini S; Rendina R; Coccaro C; D'Armiento M; Ulisse S
    Endocrine; 2016 May; 52(2):287-95. PubMed ID: 26215279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antineoplastic activity of the multitarget tyrosine kinase inhibitors CLM3 and CLM94 in medullary thyroid cancer in vitro.
    Ferrari SM; Fallahi P; La Motta C; Bocci G; Corrado A; Materazzi G; Galleri D; Piaggi S; Danesi R; Da Settimo F; Miccoli P; Antonelli A
    Surgery; 2014 Nov; 156(5):1167-76. PubMed ID: 25151558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thiocoraline alters neuroendocrine phenotype and activates the Notch pathway in MTC-TT cell line.
    Tesfazghi S; Eide J; Dammalapati A; Korlesky C; Wyche TP; Bugni TS; Chen H; Jaskula-Sztul R
    Cancer Med; 2013 Oct; 2(5):734-43. PubMed ID: 24403239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sorafenib and Mek inhibition is synergistic in medullary thyroid carcinoma in vitro.
    Koh YW; Shah MH; Agarwal K; McCarty SK; Koo BS; Brendel VJ; Wang C; Porter K; Jarjoura D; Saji M; Ringel MD
    Endocr Relat Cancer; 2012 Feb; 19(1):29-38. PubMed ID: 22109971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.